Literature DB >> 24157977

Prognostic factors for chemotherapy induced nausea and vomiting.

David Warr1.   

Abstract

PURPOSE: to review the topic of prognostic factors for chemotherapy-induced nausea and vomiting. Multiple patient factors such as age, gender and alcohol intake have been found that affect the likelihood of emesis with a given chemotherapy. Pharmacogenomics has also been explored as a cause for variation in emetic response. In theory these risk factors could be used to optimize antiemetic therapy for individual patients but guidelines for prophylactic antiemetics are based solely upon the type of chemotherapy administered. Attempts to identify subgroups of patients for whom guidelines recommendations are suboptimal have thus far been unsuccessful except for those with a poor experience in a previous cycle of the same chemotherapy. At present, there is no basis for deviating from evidence-based guidelines when prescribing antiemetics prior to the first cycle of chemotherapy.
© 2013 Published by Elsevier B.V.

Entities:  

Keywords:  Cancer; Chemotherapy; Emesis; Prognostic

Mesh:

Year:  2013        PMID: 24157977     DOI: 10.1016/j.ejphar.2013.10.015

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.

Authors:  Kazuo Tamura; Keisuke Aiba; Toshiaki Saeki; Yoichi Nakanishi; Toshiharu Kamura; Hideo Baba; Kazuhiro Yoshida; Nobuyuki Yamamoto; Yuko Kitagawa; Yoshihiko Maehara; Mototsugu Shimokawa; Koichi Hirata; Masaki Kitajima
Journal:  Int J Clin Oncol       Date:  2015-02-15       Impact factor: 3.402

2.  Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).

Authors:  Bernardo Rapoport; Daniel Chua; Allen Poma; Sujata Arora; Yan Wang; Luis Enrique Fein
Journal:  Support Care Cancer       Date:  2015-05-05       Impact factor: 3.603

Review 3.  Symptom management during and after treatment with concurrent chemoradiotherapy for oropharyngeal cancer: A review of the literature and areas for future research.

Authors:  Heidi Mason; Mary Beth DeRubeis; Nancy Burke; Melissa Shannon; Danielle Karsies; Gregory Wolf; Avi Eisbruch; Francis Worden
Journal:  World J Clin Oncol       Date:  2016-04-10

4.  Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Authors:  Sun Young Rha; Yeonhee Park; Su Kyung Song; Chung Eun Lee; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

5.  Risk factors of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer: a prospective cohort study (YCOG1301).

Authors:  Shogo Takei; Atsushi Ishibe; Jun Watanabe; Kazuteru Watanabe; Yusuke Suwa; Shinsuke Suzuki; Kazuya Nakagawa; Hirokazu Suwa; Mitsuyoshi Ota; Yasushi Ichikawa; Chikara Kunisaki; Takeharu Yamanaka; Itaru Endo
Journal:  Int J Colorectal Dis       Date:  2020-08-28       Impact factor: 2.571

6.  Predictors of antiemetic alteration in pediatric acute myeloid leukemia.

Authors:  Jason L Freedman; Jennifer Faerber; Tammy I Kang; Dingwei Dai; Brian T Fisher; Yuan-Shung Huang; Yimei Li; Richard Aplenc; Chris Feudtner
Journal:  Pediatr Blood Cancer       Date:  2014-06-17       Impact factor: 3.167

7.  Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.

Authors:  Heidi S Donovan; Teresa L Hagan; Grace B Campbell; Michelle M Boisen; Leah M Rosenblum; Robert P Edwards; Dana H Bovbjerg; Charles C Horn
Journal:  Support Care Cancer       Date:  2016-01-08       Impact factor: 3.603

8.  Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.

Authors:  Helen Vol; Jacqueline Flank; Sara R Lavoratore; Paul C Nathan; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; L Lee Dupuis
Journal:  Support Care Cancer       Date:  2015-09-03       Impact factor: 3.603

Review 9.  [Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis].

Authors:  E Storz; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2018-05       Impact factor: 0.639

10.  Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis.

Authors:  Masato Karayama; Naoki Inui; Kazuki Tanaka; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Noriyuki Enomoto; Yutaro Nakamura; Takafumi Suda
Journal:  Med Oncol       Date:  2018-09-05       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.